Isotretinoin for acne and rosacea

Kendra D. Watson; Rachel Y. Miest; Megha M. Tollefson

doi:10.12788/j.sder.2016.023

Isotretinoin for acne and rosacea

Kendra D. Watson, Rachel Y. Miest, Megha M. Tollefson

Dermatology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Isotretinoin is a revolutionary medicine for the treatment of acne vulgaris, with new studies showing evidence of excellent clinical outcomes in treating rosacea. After 30 years of clinical experience, new insights are being gained into dosing strategies, recurrence prevention, and dose-related side effects. Previous controversial associations with inflammatory bowel diseases and mood disorders have hampered the use of this medication in some clinical situations, with new evidence disproving these claims. The teratogenicity of this medication mandates iPLEDGE compliance with government regulations. Clinicians should be knowledgeable about this medication including its side effects, teratogenicity, and its controversies in order to adequately counsel patients, dissuade fears, and obtain the best clinical outcome when treating acne and rosacea.

Original language	English (US)
Pages (from-to)	79-86
Number of pages	8
Journal	Seminars in Cutaneous Medicine and Surgery
Volume	35
Issue number	2
DOIs	https://doi.org/10.12788/j.sder.2016.023
State	Published - Jun 1 2016

ASJC Scopus subject areas

Surgery
Dermatology

Access to Document

10.12788/j.sder.2016.023

Cite this

@article{0148f9f204c94a778d6b87ef74cddd8f,

title = "Isotretinoin for acne and rosacea",

abstract = "Isotretinoin is a revolutionary medicine for the treatment of acne vulgaris, with new studies showing evidence of excellent clinical outcomes in treating rosacea. After 30 years of clinical experience, new insights are being gained into dosing strategies, recurrence prevention, and dose-related side effects. Previous controversial associations with inflammatory bowel diseases and mood disorders have hampered the use of this medication in some clinical situations, with new evidence disproving these claims. The teratogenicity of this medication mandates iPLEDGE compliance with government regulations. Clinicians should be knowledgeable about this medication including its side effects, teratogenicity, and its controversies in order to adequately counsel patients, dissuade fears, and obtain the best clinical outcome when treating acne and rosacea.",

author = "Watson, {Kendra D.} and Miest, {Rachel Y.} and Tollefson, {Megha M.}",

note = "Publisher Copyright: {\textcopyright} 2016 Frontline Medical Communications.",

year = "2016",

month = jun,

day = "1",

doi = "10.12788/j.sder.2016.023",

language = "English (US)",

volume = "35",

pages = "79--86",

journal = "Seminars in Cutaneous Medicine and Surgery",

issn = "1085-5629",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Isotretinoin for acne and rosacea

AU - Watson, Kendra D.

AU - Miest, Rachel Y.

AU - Tollefson, Megha M.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Isotretinoin is a revolutionary medicine for the treatment of acne vulgaris, with new studies showing evidence of excellent clinical outcomes in treating rosacea. After 30 years of clinical experience, new insights are being gained into dosing strategies, recurrence prevention, and dose-related side effects. Previous controversial associations with inflammatory bowel diseases and mood disorders have hampered the use of this medication in some clinical situations, with new evidence disproving these claims. The teratogenicity of this medication mandates iPLEDGE compliance with government regulations. Clinicians should be knowledgeable about this medication including its side effects, teratogenicity, and its controversies in order to adequately counsel patients, dissuade fears, and obtain the best clinical outcome when treating acne and rosacea.

AB - Isotretinoin is a revolutionary medicine for the treatment of acne vulgaris, with new studies showing evidence of excellent clinical outcomes in treating rosacea. After 30 years of clinical experience, new insights are being gained into dosing strategies, recurrence prevention, and dose-related side effects. Previous controversial associations with inflammatory bowel diseases and mood disorders have hampered the use of this medication in some clinical situations, with new evidence disproving these claims. The teratogenicity of this medication mandates iPLEDGE compliance with government regulations. Clinicians should be knowledgeable about this medication including its side effects, teratogenicity, and its controversies in order to adequately counsel patients, dissuade fears, and obtain the best clinical outcome when treating acne and rosacea.

UR - http://www.scopus.com/inward/record.url?scp=84988476677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988476677&partnerID=8YFLogxK

U2 - 10.12788/j.sder.2016.023

DO - 10.12788/j.sder.2016.023

M3 - Article

C2 - 27416313

AN - SCOPUS:84988476677

SN - 1085-5629

VL - 35

SP - 79

EP - 86

JO - Seminars in Cutaneous Medicine and Surgery

JF - Seminars in Cutaneous Medicine and Surgery

IS - 2

ER -

Isotretinoin for acne and rosacea

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this